{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:01:08Z","timestamp":1784890868333,"version":"3.55.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"DOI":"10.1186\/s13054-026-06142-2","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:16:05Z","timestamp":1781943365000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of extended versus continuous infusion of beta-lactam antibiotics for severe infection: a network meta-analysis of randomized trials"],"prefix":"10.1186","volume":"30","author":[{"given":"Liujun","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"issue":"8","key":"6142_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s00134-020-06151-x","volume":"46","author":"C Fleischmann-Struzek","year":"2020","unstructured":"Fleischmann-Struzek C, Mellhammar L, Rose N, et al. Incidence and mortality of hospital- and icu-treated sepsis: results from an updated and expanded systematic review and meta-analysis. Intensive Care Med. 2020;46(8):1552\u201362.","journal-title":"Intensive Care Med"},{"issue":"11","key":"6142_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intens Care Med. 2021;47(11):1181\u2013247.","journal-title":"Intens Care Med"},{"issue":"1","key":"6142_CR3","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40560-020-00504-w","volume":"8","author":"C Scharf","year":"2020","unstructured":"Scharf C, Liebchen U, Paal M, et al. The higher the better? defining the optimal beta-lactam target for critically Ill patients to reach infection resolution and improve outcome. J Intens Care. 2020;8(1):86.","journal-title":"J Intens Care"},{"issue":"1","key":"6142_CR4","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13054-018-2155-1","volume":"22","author":"RP Veiga","year":"2018","unstructured":"Veiga RP, Paiva J. Pharmacokinetics-pharmacodynamics Issues relevant for the clinical use of beta-lactam antibiotics in critically Ill patients. Crit Care. 2018;22(1):233\u20134.","journal-title":"Crit Care"},{"issue":"6","key":"6142_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically Ill adult patients: a position paper. Intens Care Med. 2020;46(6):1127\u201353.","journal-title":"Intens Care Med"},{"issue":"3","key":"6142_CR6","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1093\/jac\/dkaf013","volume":"80","author":"A Smekal","year":"2025","unstructured":"Smekal A, Swartling M, Furebring M, et al. Short, extended and continuous infusion of \u03b2-Lactams: predicted impact on target attainment and risk for toxicity in an icu patient cohort. J Antimicrob Chemother. 2025;80(3):876\u201384.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"6142_CR7","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current -lactam antibiotic doses sufficient for critically Ill patients? Clin Infect Dis. 2014;58(8):1072\u201383.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"6142_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2298\/VSP241213029T","volume":"82","author":"N Tomic","year":"2025","unstructured":"Tomic N, Vukmirovic S, Sabo S, et al. Compliance of extended infusion of piperacillin\/tazobactam with the desired pharmacokinetic\/pharmacodynamic index in septic patients. Vojnosanit Pregl. 2025;82(5):263\u201371.","journal-title":"Vojnosanit Pregl"},{"issue":"6","key":"6142_CR9","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1128\/AAC.04166-14","volume":"59","author":"S Jaruratanasirikul","year":"2015","unstructured":"Jaruratanasirikul S, Thengyai S, Wongpoowarak W, et al. Population pharmacokinetics and monte carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically Ill patients in intensive care units. Antimicrob Agents Chemother. 2015;59(6):2995\u20133001.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"6142_CR10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.4103\/0366-6999.205859","volume":"130","author":"H Zhao","year":"2017","unstructured":"Zhao H, Gu J, Lyu J, et al. Pharmacokinetic and pharmacodynamic efficacies of continuous versus intermittent administration of meropenem in patients with severe sepsis and septic shock. Chin Med J. 2017;130(10):1139\u201345.","journal-title":"Chin Med J"},{"issue":"6","key":"6142_CR11","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/cid\/ciaf038","volume":"80","author":"AM Tilanus","year":"2025","unstructured":"Tilanus AM, Shields RK, Lodise TP, et al. Translating pharmacokinetic-pharmacodynamic principles into improved methodology for clinical trials that compare intermittent with prolonged infusion of beta-lactam antibiotics. Clin Infect Dis. 2025;80(6):1275\u201380.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"6142_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201667","volume":"13","author":"Z Yu","year":"2018","unstructured":"Yu Z, Pang X, Wu X, et al. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis. PLoS ONE. 2018;13(7):e201667.","journal-title":"PLoS ONE"},{"issue":"1","key":"6142_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40560-020-00490-z","volume":"8","author":"Y Kondo","year":"2020","unstructured":"Kondo Y, Ota K, Imura H, et al. Prolonged versus intermittent \u03b2-lactam antibiotics intravenous infusion strategy in sepsis or septic shock patients: a systematic review with meta-analysis and trial sequential analysis of randomized trials. J Intens Care. 2020;8(1):77.","journal-title":"J Intens Care"},{"issue":"2","key":"6142_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s13318-017-0439-5","volume":"43","author":"YR Lee","year":"2018","unstructured":"Lee YR, Miller PD, Alzghari SK, et al. Continuous infusion versus intermittent bolus of beta-lactams in critically Ill patients with respiratory infections: a systematic review and meta-analysis. Eur J Drug Metab Pharmacokinet. 2018;43(2):155\u201370.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"6142_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/CCM.0000000000002836","volume":"46","author":"NJ Rhodes","year":"2018","unstructured":"Rhodes NJ, Liu J, O\u2019Donnell JN, et al. Prolonged infusion piperacillin-tazobactam decreases mortality and improves outcomes in severely Ill patients results of a systematic review and meta-analysis. Crit Care Med. 2018;46(2):236\u201343.","journal-title":"Crit Care Med"},{"issue":"1","key":"6142_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/S1473-3099(17)30615-1","volume":"18","author":"KZ Vardakas","year":"2018","unstructured":"Vardakas KZ, Voulgaris GL, Maliaros A, et al. prolonged versus short-term intravenous infusion of antipseudomonal \u03b2-Lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis. 2018;18(1):108\u201320.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"6142_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2025.102634","volume":"31","author":"Z Mu","year":"2025","unstructured":"Mu Z, Wang J, Mu E. Impact of prolonged versus intermittent infusion of meropenem on mortality and clinical outcomes in patients with severe infection: a systematic review and meta-analysis. J Infect Chemother. 2025;31(3):102634.","journal-title":"J Infect Chemother"},{"issue":"10","key":"6142_CR18","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.1097\/JS9.0000000000002812","volume":"111","author":"Y Qiu","year":"2025","unstructured":"Qiu Y, Hu Q, Xu W, et al. Prolonged versus short-term infusion of meropenem for the treatment of sepsis: a systematic review and meta-analysis. Int j surg. 2025;111(10):7213\u201321.","journal-title":"Int j surg"},{"key":"6142_CR19","doi-asserted-by":"publisher","first-page":"1580116","DOI":"10.3389\/fmed.2025.1580116","volume":"12","author":"Y Wang","year":"2025","unstructured":"Wang Y, Li Y, Gao M, et al. Continuous vs intermittent meropenem infusion in critically Ill patients with sepsis: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis. Front Med. 2025;12:1580116.","journal-title":"Front Med"},{"issue":"10","key":"6142_CR20","doi-asserted-by":"publisher","first-page":"e725","DOI":"10.1128\/aac.00732-25","volume":"69","author":"Y Li","year":"2025","unstructured":"Li Y, Roberts JA, Abdul-Aziz MH, et al. Continuous or extended vs intermittent infusions of beta-lactam antibiotics on icu patients with pneumonia: a systematic review and meta-analysis of randomized controlled trials. Antimicrob Agents Chemother. 2025;69(10):e725\u201332.","journal-title":"Antimicrob Agents Chemother"},{"key":"6142_CR21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jcrc.2019.04.013","volume":"52","author":"SAM Dhaese","year":"2019","unstructured":"Dhaese SAM, Thooft ADJ, Farkas A, et al. Early target attainment of continuous infusion piperacillin\/tazobactam and meropenem in critically Ill patients: a prospective observational study. J Crit Care. 2019;52:75\u20139.","journal-title":"J Crit Care"},{"issue":"1","key":"6142_CR22","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/jac\/dkv288","volume":"71","author":"MH Abdul-Aziz","year":"2015","unstructured":"Abdul-Aziz MH, Lipman J, Akova M, et al. Is Prolonged infusion of piperacillin\/tazobactam and meropenem in critically Ill patients associated with improved pharmacokinetic\/pharmacodynamic and patient outcomes? an observation from the defining antibiotic levels in intensive care unit patients (dali) cohort. J Antimicrob Chemother. 2015;71(1):196\u2013207.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"6142_CR23","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/cid\/ciy258","volume":"67","author":"R Ram","year":"2018","unstructured":"Ram R, Halavy Y, Amit O, et al. Extended vs bolus infusion of broad-spectrum \u03b2-lactams for febrile neutropenia: an unblinded, randomized trial. Clin Infect Dis. 2018;67(8):1153\u201360.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"6142_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.cger.2017.01.002","volume":"33","author":"E Garpestad","year":"2017","unstructured":"Garpestad E, Devlin JW. Polypharmacy and delirium in critically ill older adults. Clin Geriatr Med. 2017;33(2):189\u2013203.","journal-title":"Clin Geriatr Med"},{"key":"6142_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.734045","volume":"12","author":"M Kurczewska-Michalak","year":"2021","unstructured":"Kurczewska-Michalak M, Lewek P, Jankowska-Pola\u0144ska B, et al. Polypharmacy management in the older adults: a scoping review of available interventions. Front Pharmacol. 2021;12:734045.","journal-title":"Front Pharmacol"},{"issue":"6","key":"6142_CR26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.31083\/ph.2019.8215","volume":"74","author":"C Curti","year":"2019","unstructured":"Curti C, Souab HK, Lamy E, et al. Stability studies of antipyocyanic beta-lactam antibiotics used in continuous infusion. Pharmazie. 2019;74(6):357\u201362.","journal-title":"Pharmazie"},{"issue":"14","key":"6142_CR27","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.2146\/ajhp161058","volume":"75","author":"J Biltoft","year":"2018","unstructured":"Biltoft J, Finneman L. Clinical and financial effects of smart pump-electronic medical record interoperability at a hospital in a regional health system. Am J Health Syst Pharm. 2018;75(14):1064\u20138.","journal-title":"Am J Health Syst Pharm"},{"key":"6142_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"11","key":"6142_CR29","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1164\/rccm.201505-0857OC","volume":"192","author":"JM Dulhunty","year":"2015","unstructured":"Dulhunty JM, Roberts JA, Davis JS, et al. A multicenter randomized trial of continuous versus intermittent \u03b2-lactam infusion in severe sepsis. Am J Respir Crit Care Med. 2015;192(11):1298\u2013305.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"6142_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/FTD.0000000000001144","volume":"46","author":"NF Maranchick","year":"2024","unstructured":"Maranchick NF, Trillo-Alvarez C, Kariyawasam V, et al. A randomized clinical trial of Bayesian-guided beta-lactam infusion strategy and associated bacterial resistance and clinical outcomes in patients with severe pneumonia. Ther Drug Monit. 2024;46(1):95\u2013101.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"6142_CR31","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00134-015-4188-0","volume":"42","author":"MH Abdul-Aziz","year":"2016","unstructured":"Abdul-Aziz MH, Sulaiman H, Mat-Nor M, et al. Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intens Care Med. 2016;42(10):1535\u201345.","journal-title":"Intens Care Med"},{"issue":"08","key":"6142_CR32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.5414\/CPP43360","volume":"43","author":"B Georges","year":"2005","unstructured":"Georges B, Conil JM, Cougot P, et al. Cefepime in critically Ill patients: continuous infusion vs an intermittent dosing regimen. Int J Clin Pharmacol Ther. 2005;43(08):360\u20139.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"6142_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/cc11405","volume":"16","author":"I Chytra","year":"2012","unstructured":"Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care. 2012;16(3):R113.","journal-title":"Crit Care"},{"issue":"2","key":"6142_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/cid\/cis856","volume":"56","author":"JM Dulhunty","year":"2012","unstructured":"Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind. Randomized Controlled Trial Clinical Infectious Diseases. 2012;56(2):236\u201344.","journal-title":"Randomized Controlled Trial Clinical Infectious Diseases"},{"issue":"6","key":"6142_CR35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0924-8579(01)00329-6","volume":"17","author":"DP Nicolau","year":"2001","unstructured":"Nicolau DP, McNabb J, Lacy MK, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents. 2001;17(6):497\u2013504.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"6142_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2025.106487","volume":"90","author":"AB Khan","year":"2025","unstructured":"Khan AB, Abdul-Aziz MH, Hindle L, et al. Continuous versus intermittent bolus dosing of beta-lactam antibiotics in a south african multi-disciplinary intensive care unit: a randomized controlled trial. J Infect. 2025;90(5):106487.","journal-title":"J Infect"},{"issue":"2","key":"6142_CR37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/jama.2023.10598","volume":"330","author":"G Monti","year":"2023","unstructured":"Monti G, Bradic N, Marzaroli M, et al. Continuous vs intermittent meropenem administration in critically Ill patients with sepsis: the mercy randomized clinical trial. JAMA. 2023;330(2):141\u201351.","journal-title":"JAMA"},{"issue":"8","key":"6142_CR38","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1001\/jama.2024.9779","volume":"332","author":"JM Dulhunty","year":"2024","unstructured":"Dulhunty JM, Brett SJ, De Waele JJ, et al. Continuous vs intermittent \u03b2-lactam antibiotic infusions in critically ill patients with sepsis: the bling iii randomized clinical trial. JAMA. 2024;332(8):629\u201337.","journal-title":"JAMA"},{"issue":"3","key":"6142_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/antibiotics13030229","volume":"13","author":"CA \u00c1lvarez-Moreno","year":"2024","unstructured":"\u00c1lvarez-Moreno CA, Nocua-B\u00e1ez LC, Ortiz G, et al. Efficacy of continuous vs intermittent administration of cefepime in adult ICU patients with gram-negative bacilli bacteremia: a randomized double-blind clinical study. Antibiotics. 2024;13(3):229.","journal-title":"Antibiotics"},{"issue":"6","key":"6142_CR40","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0002-9610(00)00388-3","volume":"179","author":"SD Hanes","year":"2000","unstructured":"Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically Ill trauma patients. Am J Surg. 2000;179(6):436\u201340.","journal-title":"Am J Surg"},{"issue":"1","key":"6142_CR41","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1093\/jac\/dkp139","volume":"64","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Kirkpatrick CMJ, Roberts MS, et al. Meropenem dosing in critically Ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? monte carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64(1):142\u201350.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"6142_CR42","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1097\/CCM.0b013e3181968e44","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts JA, Roberts MS, Robertson TA, et al. piperacillin penetration into tissue of critically Ill patients with sepsis-bolus versus continuous administration? Crit Care Med. 2009;37(3):926\u201333.","journal-title":"Crit Care Med"},{"issue":"9","key":"6142_CR43","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1128\/AAC.01318-06","volume":"51","author":"SG Sakka","year":"2007","unstructured":"Sakka SG, Glauner AK, Bulitta JB, et al. Population Pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically Ill patients in a randomized. Control Trial Antimicrob Agents Chemother. 2007;51(9):3304\u201310.","journal-title":"Control Trial Antimicrob Agents Chemother"},{"issue":"11","key":"6142_CR44","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1128\/AAC.00329-06","volume":"50","author":"WK Lau","year":"2006","unstructured":"Lau WK, Mercer D, Itani KM, et al. randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother. 2006;50(11):3556\u201361.","journal-title":"Antimicrob Agents Chemother"},{"key":"6142_CR45","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/TCRM.S145681","volume":"14","author":"Y Lyu","year":"2018","unstructured":"Lyu Y, Yang Y, Li X, et al. selection of piperacillin\/tazobactam infusion mode guided by sofa score in cancer patients with hospital-acquired pneumonia: a randomized controlled study. Ther Clin Risk Manag. 2018;14:31\u20137.","journal-title":"Ther Clin Risk Manag"},{"issue":"15","key":"6142_CR46","first-page":"2949","volume":"37","author":"Z Li","year":"2010","unstructured":"Li Z, Zhang Y, Wang Z, et al. clinical efficacy of continuous infusion of piperacillin\/tazobactam in severe pneumonia patients: a randomized controlled clinical study. Mod Prev Med. 2010;37(15):2949\u201351.","journal-title":"Mod Prev Med"},{"issue":"1","key":"6142_CR47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/phar.1875","volume":"37","author":"S Fan","year":"2017","unstructured":"Fan S, Shum H, Cheng W, et al. Clinical outcomes of extended versus intermittent infusion of piperacillin\/tazobactam in critically Ill patients: a prospective clinical trial. Pharmacother J Human Pharmacol Drug Ther. 2017;37(1):109\u201319.","journal-title":"Pharmacother J Human Pharmacol Drug Ther."},{"issue":"9","key":"6142_CR48","first-page":"644","volume":"26","author":"Z Wang","year":"2014","unstructured":"Wang Z, Shan T, Liu Y, et al. Comparison of 3-hour and 30-minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial. Zhonghua wei zhong bing ji jiu yi xue. 2014;26(9):644\u20139.","journal-title":"Zhonghua wei zhong bing ji jiu yi xue"},{"issue":"1","key":"6142_CR49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/sja.SJA_148_17","volume":"12","author":"MA Ammar","year":"2018","unstructured":"Ammar MA, Abdalla W. Effect of extended infusion of meropenem and nebulized amikacin on gram-negative multidrug-resistant ventilator-associated pneumonia. Saudi J Anaesth. 2018;12(1):89\u201394.","journal-title":"Saudi J Anaesth"},{"issue":"2","key":"6142_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cmi.2024.10.006","volume":"31","author":"J Laporte-Amargos","year":"2025","unstructured":"Laporte-Amargos J, Carmona-Torre F, Huguet M, et al. Efficacy of extended infusion of \u03b2-Lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (beatle): a randomized, multicentre, open-label, superiority clinical trial. Clin Microbiol Infect. 2025;31(2):211\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"6142_CR51","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1177\/1078155216687151","volume":"24","author":"RH Wrenn","year":"2018","unstructured":"Wrenn RH, Cluck D, Kennedy L, et al. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia. J Oncol Pharm Pract. 2018;24(3):170\u20135.","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"6142_CR52","doi-asserted-by":"publisher","first-page":"10882","DOI":"10.1038\/s41598-022-12861-7","volume":"12","author":"CM Naiim","year":"2022","unstructured":"Naiim CM, Elmazar MM, Sabri NA, et al. Extended infusion of piperacillin-tazobactam versus intermittent infusion in critically Ill egyptian patients: a cost-effectiveness study. Sci Rep. 2022;12(1):10882.","journal-title":"Sci Rep"},{"issue":"4","key":"6142_CR53","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ijantimicag.2014.05.011","volume":"44","author":"M Lip\u0161","year":"2014","unstructured":"Lip\u0161 M, \u0160iller M, Strojil J, et al. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions. Int J Antimicrob Agents. 2014;44(4):358\u201362.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"6142_CR54","first-page":"479","volume":"25","author":"Y L\u00fc","year":"2013","unstructured":"L\u00fc Y, Yan Z, Wang D, et al. Treatment study of hospital acquired pneumonia by optimizing dosing regimen of Piperacillin\/tazobactam: prolonged vs regular infusion. Zhonghua wei zhong bing ji jiu yi xue. 2013;25(8):479\u201383.","journal-title":"Zhonghua wei zhong bing ji jiu yi xue."},{"issue":"2","key":"6142_CR55","first-page":"251","volume":"18","author":"D Wang","year":"2008","unstructured":"Wang D, Zhang J, Zhang L, et al. An improving meropenem infusion scheme therapy for acinetobacter baumannii pneumonia in ICU:a clinical analysis. Chin J Nosocomiol. 2008;18(2):251\u20133.","journal-title":"Chin J Nosocomiol"},{"issue":"09","key":"6142_CR56","first-page":"8","volume":"29","author":"Z Lu","year":"2012","unstructured":"Lu Z, Ma Z, Fang X. Therapeutic effect of administration time of meropenem on pseudomonas aeruginosa infection. Mil Nurs. 2012;29(09):8\u201311.","journal-title":"Mil Nurs"},{"issue":"14","key":"6142_CR57","first-page":"90","volume":"25","author":"H Ding","year":"2010","unstructured":"Ding H, Yu J, Zuo X, et al. Research on optimal infusion speed of meropenem in treating drug-resistant gram-negative bacillus infections. J Nurs Sci. 2010;25(14):90\u20132.","journal-title":"J Nurs Sci"},{"issue":"11","key":"6142_CR58","first-page":"1261","volume":"43","author":"D Liu","year":"2023","unstructured":"Liu D, Su T, Wu T, et al. The effect of different infusion durations of cefepime on clinical efficacy and outcomes in patients with febrile neutropenia after chemotherapy. Chin J Hosp Pharm. 2023;43(11):1261\u20135.","journal-title":"Chin J Hosp Pharm"},{"key":"6142_CR59","first-page":"1306","volume":"09","author":"S Li","year":"2008","unstructured":"Li S, Wang D. A clinical study on prolonged infusion of meropenem for severe infections in the surgical intensive care unit. Chin J Nosocomiol. 2008;09:1306\u20139.","journal-title":"Chin J Nosocomiol"},{"issue":"14","key":"6142_CR60","first-page":"1974","volume":"26","author":"L Zhang","year":"2015","unstructured":"Zhang L, Wu L, Wu Q. A clinical study on prolonged infusion of meropenem for severe pneumonia. Chin Pharm. 2015;26(14):1974\u20136.","journal-title":"Chin Pharm"},{"issue":"16","key":"6142_CR61","first-page":"3476","volume":"21","author":"L Ye","year":"2011","unstructured":"Ye L, Cai T, Jin Y, et al. A clinical study on prolonged infusion of piperacillin\/tazobactam for gram-negative bacterial infections. Chin J Nosocomiol. 2011;21(16):3476\u20139.","journal-title":"Chin J Nosocomiol"},{"issue":"11","key":"6142_CR62","doi-asserted-by":"publisher","first-page":"635511529","DOI":"10.1177\/03000605251394839","volume":"53","author":"R Zhang","year":"2025","unstructured":"Zhang R, Qin Y, Lv Y, et al. Pharmacokinetics of imipenem in critically ill patients: continuous infusion versus extended infusion in a real-world study. J Int Med Res. 2025;53(11):635511529.","journal-title":"J Int Med Res"},{"issue":"2","key":"6142_CR63","doi-asserted-by":"publisher","first-page":"162","DOI":"10.18683\/germs.2024.1428","volume":"14","author":"B Alawyia","year":"2024","unstructured":"Alawyia B, Fathima S, Spernovasilis N, et al. Continuous versus intermittent infusion of beta-lactam antibiotics: where do we stand today? A Narr Rev Germs. 2024;14(2):162\u201378.","journal-title":"A Narr Rev Germs"},{"issue":"3","key":"6142_CR64","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pharma.2013.12.006","volume":"72","author":"D Attivi","year":"2014","unstructured":"Attivi D, Gibaud S. Continuous infusion of piperacillin\/tazobactam in patients with severe infections: a possible pharmacokinetic optimisation? Ann Pharm Fr. 2014;72(3):146\u201351.","journal-title":"Ann Pharm Fr"},{"key":"6142_CR65","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.2147\/IDR.S469313","volume":"17","author":"Y Han","year":"2024","unstructured":"Han Y, Zhu J, Liu J, et al. Adequacy of the dosing and infusion time of ceftazidime\/avibactam for the treatment of gram-negative bacterial infections: A PK\/PD simulation study. Infect Drug Resist. 2024;17:2823\u201332.","journal-title":"Infect Drug Resist"},{"issue":"4","key":"6142_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13040296","volume":"13","author":"M Gatti","year":"2024","unstructured":"Gatti M, Rinaldi M, Tonetti T, et al. Comparative impact of an optimized PK\/PD target attainment of piperacillin-tazobactam vs. meropenem on the trend over time of SOFA score and inflammatory biomarkers in critically ill patients receiving continuous infusion monotherapy for treating documented gram-negative BSIs and\/or VAP. Antibiotics. 2024;13(4):296.","journal-title":"Antibiotics"},{"issue":"4","key":"6142_CR67","doi-asserted-by":"publisher","first-page":"107309","DOI":"10.1016\/j.ijantimicag.2024.107309","volume":"64","author":"H Rolain","year":"2024","unstructured":"Rolain H, Schwartz Z, Jubrail R, et al. Meta-analysis on Safety of Standard vs Prolonged Infusion of Beta-Lactams. Int J Antimicrob Agents. 2024;64(4):107309.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"6142_CR68","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jama.2024.0179","volume":"331","author":"LJ Schlapbach","year":"2024","unstructured":"Schlapbach LJ, Watson RS, Sorce LR, et al. International Consensus Criteria for Pediatric Sepsis and Septic Shock. JAMA. 2024;331(8):665.","journal-title":"JAMA"},{"key":"6142_CR69","doi-asserted-by":"crossref","unstructured":"Oliveira E Silva PG, Cerqueira Batista Filho LA, P\u00e9rez Flores I, et al. Community-acquired pneumonia: epidemiology, diagnosis, prognostic severity scales, and new therapeutic options. Medwave. 2023;23(11):e2719.","DOI":"10.5867\/medwave.2023.11.2719"},{"issue":"12","key":"6142_CR70","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00134-024-07694-z","volume":"50","author":"I Martin-Loeches","year":"2024","unstructured":"Martin-Loeches I, Singer M, Leone M. Sepsis: key insights, future directions, and immediate goals. A review and expert opinion. Intensive Care Med. 2024;50(12):2043\u20139.","journal-title":"Intensive Care Med"},{"issue":"1","key":"6142_CR71","doi-asserted-by":"publisher","DOI":"10.1017\/ash.2023.179","volume":"3","author":"AV Khole","year":"2023","unstructured":"Khole AV, Dionne E, Zitek-Morrison E, et al. Cefepime extended infusion versus intermittent infusion: clinical and cost evaluation. Antimicrob Stewardsh Healthcare Epidemiol. 2023;3(1):e119.","journal-title":"Antimicrob Stewardsh Healthcare Epidemiol"},{"issue":"5","key":"6142_CR72","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61050922","volume":"61","author":"R Hirani","year":"2025","unstructured":"Hirani R, Podder D, Stala O, et al. Strategies to reduce hospital length of stay: evidence and challenges. Medicina (Kaunas). 2025;61(5):922.","journal-title":"Medicina (Kaunas)"},{"issue":"9","key":"6142_CR73","doi-asserted-by":"publisher","first-page":"e2125846","DOI":"10.1001\/jamanetworkopen.2021.25846","volume":"4","author":"SM Siddique","year":"2021","unstructured":"Siddique SM, Tipton K, Leas B, et al. Interventions to reduce hospital length of stay in high-risk populations. JAMA Netw Open. 2021;4(9):e2125846.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"6142_CR74","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1592\/phco.22.7.471.33665","volume":"22","author":"EM Grant","year":"2002","unstructured":"Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and pharmacoeconomics of a continuous\u2010infusion piperacillin\u2010tazobactam program in a large community teaching hospital. Pharmacotherapy J Human Pharmacol Drug Ther. 2002;22(4):471\u201383.","journal-title":"Pharmacotherapy J Human Pharmacol Drug Ther"},{"issue":"7","key":"6142_CR75","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1177\/1060028015579427","volume":"49","author":"L Brunetti","year":"2015","unstructured":"Brunetti L, Poustchi S, Cunningham D, et al. Clinical and economic impact of empirical extended-infusion piperacillin-tazobactam in a community medical center. Ann Pharmacother. 2015;49(7):754\u201360.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"6142_CR76","volume":"15","author":"A Lokhandwala","year":"2023","unstructured":"Lokhandwala A, Patel P, Isaak AK, et al. Comparison of the effectiveness of prolonged infusion and intermittent infusion of meropenem in patients with sepsis: a meta-analysis. Cureus. 2023;15(10):e46990.","journal-title":"Cureus"},{"issue":"3","key":"6142_CR77","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jinf.2023.06.023","volume":"87","author":"J Laporte-Amargos","year":"2023","unstructured":"Laporte-Amargos J, Ulldemolins M, Puig-Asensio M, et al. Prolonged vs short-term infusion of \u03b2-lactam antibiotics for the treatment of febrile neutropenia: a systematic review and meta-analysis. J Infect. 2023;87(3):190\u20138.","journal-title":"J Infect"},{"issue":"6","key":"6142_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60060929","volume":"60","author":"A Konkayev","year":"2024","unstructured":"Konkayev A, Kadralinova A, Azimova B, et al. Usage of meropenem continuous infusion for treatment of infectious complications in orthopedic elderly patients with anemia: a case series. Medicina. 2024;60(6):929.","journal-title":"Medicina"},{"issue":"8","key":"6142_CR79","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1001\/jama.2024.9803","volume":"332","author":"MH Abdul-Aziz","year":"2024","unstructured":"Abdul-Aziz MH, Hammond NE, Brett SJ, et al. Prolonged vs intermittent infusions of \u03b2-lactam antibiotics in adults with sepsis or septic shock. JAMA. 2024;332(8):638.","journal-title":"JAMA"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-026-06142-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06142-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-026-06142-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:02:23Z","timestamp":1784887343000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13054-026-06142-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6142"],"URL":"https:\/\/doi.org\/10.1186\/s13054-026-06142-2","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study does not require ethical approval because the meta-analysis is based on published research and the original data are anonymous.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"383"}}